Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

NCT01879020 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: TA-8995
DRUG: TA-8995
DRUG: TA-8995
DRUG: TA-8995
DRUG: TA-8995
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation